Skip to main
PRME
PRME logo

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc is positioned for substantial growth, with projections indicating risk-adjusted revenues from its PM577 program escalating from $32 million in 2030 to $980 million by 2035, highlighting a robust future revenue stream driven by its innovative Prime Editing technology. The company’s advancing pipeline, particularly in Wilson's Disease and its in vivo gene editing efforts, aligns with significant unmet medical needs and showcases a high likelihood of technical success based on strong preclinical data. Furthermore, anticipated positive readouts from ongoing trials could enhance investor interest and confidence in Prime Medicine's transformative capabilities within the gene editing landscape.

Bears say

The analysis highlights several fundamental concerns regarding Prime Medicine Inc.'s stock outlook, particularly relating to regulatory approval and clinical trial recruitment challenges. The potential for downward revisions in projections exists if the company struggles to gain regulatory approval for its products, especially if the regulatory pathway proves more complex than anticipated. Additionally, pricing concerns regarding the market's ability to absorb the cost of Prime's therapies, alongside safety risks associated with gene editing technology, further underpin a negative outlook on the company's financial stability and growth prospects.

PRME has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 14 analysts, PRME has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.